Quinolones - a cure which became a threat: Accelerating resistance development demands stricter indications;Kinoloner - Bot som blivit hot: Accelererande resistensutveckling kräver skärpta indikationer

Lakartidningen

Volumn 102, Issue 48, 2005, Pages 3651-3659

  Lytsy, Birgitta ^a,b   Cars, Otto ^a   Torell, Erik ^a,b  

^a Akademiska Laboratoriet ^*  (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLONE DERIVATIVE;

ANIMAL; ANTIBIOTIC RESISTANCE; DRUG UTILIZATION; EUROPE; HUMAN; MULTIDRUG RESISTANCE; PENICILLIN RESISTANCE; PRACTICE GUIDELINE; REVIEW; STATISTICS;

ANIMALS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG UTILIZATION; EUROPE; FLUOROQUINOLONES; HUMANS; METHICILLIN RESISTANCE; PRACTICE GUIDELINES; VANCOMYCIN RESISTANCE;

EID: 33644751801     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 2003;51(5):1109-17.
2. Zervos MJ, Hershberger E, Nicolau DP, Ritchie DJ, Blackner LK, Coyle EA, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003;37(12):1643-8.
3. Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis 2002;2(9):530-8.
4. Tillotson G, Zhao X, Drlica K. Fluoroquinolones as pneumococcal therapy: closing the barn door before the horse escapes. Lancet Infect Dis 2001;1(3):145-6.
5. Kahlmeter G, Menday P, Cars O. Non-hospital antimicrobial usage and resistance in community-acquired Escherichia coli urinary tract infection. J Antimicrob Chemother 2003;52(6):1005-10.
6. Higgins PG, Fluit AC, Schmitz FJ. Fluoroquinolones: structure and target sites. Curr Drug Targets 2003;4(2):181-90.
7. Andersson MI, MacGowan AP. Development of the quinolones. J Antimicrob Chemother 2003;51 Suppl 1:1-11.
8. Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis 2003;22(4):203-21.
9. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis 2000;31 Suppl 2:S24-8.
10. Schmitz FJ, Higgins PG, Mayer S, Fluit AC, Dalhoff A. Activity of quinolones against gram-positive cocci: mechanisms of drug action and bacterial resistance. Eur J Clin Microbiol Infect Dis 2002;21(9):647-59.
11. Berglund T, Colucci B, Lund B, Qvarnström I, Sandström E. Ciprofloxacinresistent gonorré ökar kraftigt i Sverige. Välj rätt antibiotikum och följ upp behandlingen! Läkartidningen 2004;101(28-29):2332-5.
12. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346(10):747-50.
13. Livermore DM, James D, Reacher M, Graham C, Nichols T, Stephens P, et al. Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg Infect Dis 2002;8(5):473-8.
14. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003;9(11):1415-22.
15. Torell E, Kuhn I, Olsson-Liljequist B, Haeggman S, Hoffman BM, Lindahl C, et al. Clonality among ampicillin-resistant Enterococcus faecium isolates in Sweden and relationship with ciprofloxacin resistance. Clin Microbiol Infect 2003;9(10):1011-9.
16. Lundborg CS, Olsson E, Molstad S. Antibiotic prescribing in outpatients: a 1-week diagnosis-prescribing study in 5 counties in Sweden. Scand J Infect Dis 2002; 34(6):442-8.
17. Andre M, Molstad S, Lundborg CS, Odenholt I. Management of urinary tract infections in primary care: a repeated 1-week diagnosis-prescribing study in five counties in Sweden in 2000 and 2002. Scand J Infect Dis 2004;36(2):134-8.
18. Marimon JM, Gomariz M, Zigorraga C, Cilla G, Perez-Trallero E. Increasing prevalence of quinolone resistance in human nontyphoid Salmonella enterica isolates obtained in Spain from 1981 to 2003. Antimicrob Agents Chemother 2004;48(10):3789-93.
19. Threlfall EJ, Ward LR, Rowe B. Resistance to ciprofloxacin in non-typhoidal salmonellas from humans in England and Wales - the current situation. Clin Microbiol Infect 1999;5(3):130-4.
20. Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005;330(7489):456.